VIARTIS

 

 

 PARKINSON'S DISEASE NEWS

 

 

 

 

 

Parkinson's Disease News covers all significant new research, reports, books, and resources concerning Parkinson's Disease. Articles are chosen on the basis of their medical significance or potential interest. Our overwhelming priority is the facts, regardless of whether they contradict prevailing views or vested interests. Analysis and further information are provided either to explain the background or implications, or to balance misleading claims. If you notice errors or inadequacies, or dispute what is written, or want to propose articles, please e-mail [email protected].

                                           

 

17th May 2013 - New research

PRELADENANT CLINICAL TRIAL RESULTS FOR PARKINSON'S DISEASE

Movement Disorders [2013] Apr 15 [Epub ahead of print] (S.A.Factor, K.Wolski, D.M.Togasaki, S.Huyck, M. Cantillon, T.W.Ho, R.A.Hauser, E.Pourcher) Complete abstract

Preladenant is a selective adenosine A2A receptor antagonist under investigation for the treatment of Parkinson's Disease. Instead of directly stimulating the formation or activity of dopamine, which is what most Parkinson's Disease drugs do, it can indirectly affect the dopamine receptors, which is what dopamine agonists affect.  Two other drugs of this type that are being investigated are istradefylline (fairly unsuccessfully) and caffeine, which is in coffee, tea and cola drinks.

Preladenant was taken in 5mg dosages twice a day alongside L-dopa for nine months. Adverse reactions caused 14% of people to cease taking it. Adverse reactions experienced by some people were dyskinesia and constipation. Preladenant provided reductions in "off" time by between 1 hour 24 minutes and 1 hour 54 minutes. "On" time increased by between 1 hour 12 minutes and 1 hour 30 minutes. For a printable version of this article click here. For more news go to Parkinson's Disease News.

UPDATE : Merck are discontinuing Preladenant because it failed to show any benefit beyond that of a placebo in three studies concerning Preladenant. The results of these studies will be presented at a scientific meeting and will be submitted for publication in a peer-reviewed journal. For more information click here.

 

E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new articles are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
2006-2013  Viartis
 
2015-08-22 04:41:52
 
[email protected]